S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Are These Consumer Staples Too Cheap for Investors To Ignore?
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
3 Reasons This Tech Giant Is Going Back To Highs
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Are These Consumer Staples Too Cheap for Investors To Ignore?
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
3 Reasons This Tech Giant Is Going Back To Highs
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Are These Consumer Staples Too Cheap for Investors To Ignore?
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
3 Reasons This Tech Giant Is Going Back To Highs
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
Are These Consumer Staples Too Cheap for Investors To Ignore?
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
Markets Are Loving These Stocks 'Firing On All Cylinders'
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Etsy Gets an Upgrade and $100 Target...Is the Bottom Finally In?
3 Reasons This Tech Giant Is Going Back To Highs
NASDAQ:ONCY

Oncolytics Biotech (ONCY) Stock Forecast, Price & News

$2.12
+0.03 (+1.44%)
(As of 09/20/2023 ET)
Compare
Today's Range
$2.08
$2.18
50-Day Range
$1.98
$3.14
52-Week Range
$1.09
$3.39
Volume
317,716 shs
Average Volume
548,509 shs
Market Capitalization
$153.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.67

Oncolytics Biotech MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
261.6% Upside
$7.67 Price Target
Short Interest
Healthy
2.25% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.36mentions of Oncolytics Biotech in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.66 out of 5 stars

Medical Sector

812th out of 961 stocks

Pharmaceutical Preparations Industry

389th out of 454 stocks


ONCY stock logo

About Oncolytics Biotech (NASDAQ:ONCY) Stock

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

ONCY Price History

ONCY Stock News Headlines

Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
Oncolytics Biotech (ONCY) Receives a Buy from RBC Capital
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
5 Analysts Have This to Say About Oncolytics Biotech
Expert Ratings for Oncolytics Biotech
See More Headlines
Receive ONCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oncolytics Biotech and its competitors with MarketBeat's FREE daily newsletter.

ONCY Company Calendar

Last Earnings
8/14/2023
Today
9/20/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ONCY
Employees
29
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.67
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+261.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-19,100,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.33 per share

Miscellaneous

Free Float
72,297,000
Market Cap
$153.42 million
Optionable
Not Optionable
Beta
2.25
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Matthew C. Coffey M.B.A.
    Ph.D., Pres, CEO & Director
  • Mr. Kirk J. Look C.A.
    CA, Chief Financial Officer
  • Mr. Andrew R. de Guttadauro (Age 56)
    Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc
    Comp: $464.6k
  • Dr. Thomas C. Heineman M.D.
    Ph.D., Chief Medical Officer
  • Ms. Allison Hagerman P.Eng.
    P.M.P., VP of Product Devel.
  • Jon Patton
    Director of Investor Relations & Communication
  • Mr. John Mark Lievonen F.C.A.
    FCA, LLD, Consultant













ONCY Stock - Frequently Asked Questions

Should I buy or sell Oncolytics Biotech stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ONCY shares.
View ONCY analyst ratings
or view top-rated stocks.

What is Oncolytics Biotech's stock price forecast for 2023?

4 brokerages have issued 12 month target prices for Oncolytics Biotech's shares. Their ONCY share price forecasts range from $3.00 to $15.00. On average, they anticipate the company's stock price to reach $7.67 in the next year. This suggests a possible upside of 261.6% from the stock's current price.
View analysts price targets for ONCY
or view top-rated stocks among Wall Street analysts.

How have ONCY shares performed in 2023?

Oncolytics Biotech's stock was trading at $1.63 at the beginning of 2023. Since then, ONCY shares have increased by 30.1% and is now trading at $2.12.
View the best growth stocks for 2023 here
.

Are investors shorting Oncolytics Biotech?

Oncolytics Biotech saw a increase in short interest in August. As of August 31st, there was short interest totaling 1,630,000 shares, an increase of 38.1% from the August 15th total of 1,180,000 shares. Based on an average trading volume of 1,160,000 shares, the days-to-cover ratio is presently 1.4 days.
View Oncolytics Biotech's Short Interest
.

When is Oncolytics Biotech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our ONCY earnings forecast
.

How were Oncolytics Biotech's earnings last quarter?

Oncolytics Biotech Inc. (NASDAQ:ONCY) announced its quarterly earnings results on Monday, August, 14th. The company reported ($0.09) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.09). During the same period last year, the company earned ($0.07) earnings per share.

What is Brad Thompson's approval rating as Oncolytics Biotech's CEO?

2 employees have rated Oncolytics Biotech Chief Executive Officer Brad Thompson on Glassdoor.com. Brad Thompson has an approval rating of 56% among the company's employees. This puts Brad Thompson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Oncolytics Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), KushCo (KSHB), Organigram (OGI), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Zosano Pharma (ZSAN) and DHT (DHT).

What is Oncolytics Biotech's stock symbol?

Oncolytics Biotech trades on the NASDAQ under the ticker symbol "ONCY."

Who are Oncolytics Biotech's major shareholders?

Oncolytics Biotech's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include International Assets Investment Management LLC (0.30%), BNP Paribas Arbitrage SNC (0.10%), Bank of Montreal Can (0.05%), Osaic Holdings Inc. (0.02%), Osaic Holdings Inc. (0.02%) and Headinvest LLC (0.02%).

How do I buy shares of Oncolytics Biotech?

Shares of ONCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Oncolytics Biotech's stock price today?

One share of ONCY stock can currently be purchased for approximately $2.12.

How much money does Oncolytics Biotech make?

Oncolytics Biotech (NASDAQ:ONCY) has a market capitalization of $153.42 million. The company earns $-19,100,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis.

How can I contact Oncolytics Biotech?

Oncolytics Biotech's mailing address is 1167 Kensington Crescent Suite 210, Calgary A0, T2N 1X7. The official website for the company is www.oncolyticsbiotech.com. The company can be reached via phone at (403) 670-7377, via email at mmoore@oncolytics.ca, or via fax at 403-283-0858.

This page (NASDAQ:ONCY) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -